205 related articles for article (PubMed ID: 29420193)
1. Clinicoserological factors associated with response to steroid treatment and recurrence in patients with IgG4-related ophthalmic disease.
Hong JW; Kang S; Song MK; Ahn CJ; Sa HS
Br J Ophthalmol; 2018 Nov; 102(11):1591-1595. PubMed ID: 29420193
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of serum IgG
Woo YJ; Kim JW; Yoon JS
Br J Ophthalmol; 2017 Mar; 101(3):256-260. PubMed ID: 27215743
[TBL] [Abstract][Full Text] [Related]
3. Ocular adnexal IgG4-related disease: clinical features, outcome, and factors associated with response to systemic steroids.
Yu WK; Kao SC; Yang CF; Lee FL; Tsai CC
Jpn J Ophthalmol; 2015 Jan; 59(1):8-13. PubMed ID: 25373451
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for extraophthalmic involvement and treatment outcomes in patients with IgG4-related ophthalmic disease.
Park J; Lee MJ; Kim N; Kim JE; Park SW; Choung HK; Khwarg SI
Br J Ophthalmol; 2018 Jun; 102(6):736-741. PubMed ID: 28972022
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic features of orbital immunoglobulin G4-related disease (IgG4-RD): a case series and literature review.
Mulay K; Aggarwal E; Honavar SG
Graefes Arch Clin Exp Ophthalmol; 2015 May; 253(5):803-9. PubMed ID: 25572352
[TBL] [Abstract][Full Text] [Related]
6. Bilateral Orbital IgG4-Related Disease with Systemic and Corneal Involvement Showing an Excellent Response to Steroid and Rituximab Therapy: Report of a Case with 11 Years Follow-Up.
Berta AI; Agaimy A; Braun JM; Manger B; Kruse FE; Holbach L
Orbit; 2015; 34(5):299-301. PubMed ID: 26362833
[TBL] [Abstract][Full Text] [Related]
7. IgG4-related disease in idiopathic sclerosing orbital inflammation.
Sa HS; Lee JH; Woo KI; Kim YD
Br J Ophthalmol; 2015 Nov; 99(11):1493-7. PubMed ID: 25947555
[TBL] [Abstract][Full Text] [Related]
8. Change of Serum IgG4 in Patients with Ocular Adnexal Marginal Zone B Cell Lymphoma Associated with IgG4-Related Ophthalmic Disease After Treatment.
Wu YH; Wang LC; Yen SH; Yu WK; Kao SC; Kau HC; Tsai CC; Liu CJ
J Ocul Pharmacol Ther; 2017 Sep; 33(7):543-548. PubMed ID: 28514197
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and pathological characteristics of immunoglobulin G4-related ophthalmic disease versus orbital inflammatory pseudotumor.
Min HK; Lee YS; Yang SW; Lee J; Kwok SK; Ju JH; Kim WU; Park SH
Korean J Intern Med; 2019 Jan; 34(1):220-226. PubMed ID: 29050463
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of intravenous glucocorticoid therapy for IgG4-related ophthalmic disease.
Yang MK; Kim GJ; Choi YA; Sa HS
PLoS One; 2023; 18(4):e0284442. PubMed ID: 37075036
[TBL] [Abstract][Full Text] [Related]
11. Orbital immunoglobulin-G4-related disease: case series and literature review.
Mulay K; Aggarwal E; Jariwala M; Honavar SG
Clin Exp Ophthalmol; 2014; 42(7):682-7. PubMed ID: 24330202
[TBL] [Abstract][Full Text] [Related]
12. IgG4-Related Ophthalmic Disease. Part II: Clinical Aspects.
McNab AA; McKelvie P
Ophthalmic Plast Reconstr Surg; 2015; 31(3):167-78. PubMed ID: 25564258
[TBL] [Abstract][Full Text] [Related]
13. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease.
Khosroshahi A; Bloch DB; Deshpande V; Stone JH
Arthritis Rheum; 2010 Jun; 62(6):1755-62. PubMed ID: 20191576
[TBL] [Abstract][Full Text] [Related]
14. Treatment of immunoglobulin G4-related sialadenitis: outcomes of glucocorticoid therapy combined with steroid-sparing agents.
Hong X; Zhang YY; Li W; Liu YY; Wang Z; Chen Y; Gao Y; Sun ZP; Peng X; Su JZ; Cai ZG; Zhang L; He J; Ren LM; Yang HY; Li ZG; Yu GY
Arthritis Res Ther; 2018 Jan; 20(1):12. PubMed ID: 29382364
[TBL] [Abstract][Full Text] [Related]
15. Intraorbital corticosteroid injection for the treatment of IgG4-related ophthalmic disease.
Andrew NH; Gajdatsy A; Selva D
Br J Ophthalmol; 2016 May; 100(5):644-7. PubMed ID: 26297732
[TBL] [Abstract][Full Text] [Related]
16. Ophthalmic manifestations of IgG4-related disease: single-center experience and literature review.
Wallace ZS; Deshpande V; Stone JH
Semin Arthritis Rheum; 2014 Jun; 43(6):806-17. PubMed ID: 24513111
[TBL] [Abstract][Full Text] [Related]
17. Addition of second-line steroid sparing immunosuppressants like mycophenolate mofetil improves outcome of Immunoglobulin G4-related disease (IgG4-RD): a series from a tertiary care teaching hospital in South India.
Gupta N; Mathew J; Mohan H; Chowdhury SD; Kurien RT; Christopher DJ; Thangakunam B; Alexander M; Sivadasan A; Tamilarasi V; Valson AT; Gowri M; Kabeerdoss J; Danda D
Rheumatol Int; 2018 Feb; 38(2):203-209. PubMed ID: 28550399
[TBL] [Abstract][Full Text] [Related]
18. IgG4-related ophthalmic disease. Part I: background and pathology.
McNab AA; McKelvie P
Ophthalmic Plast Reconstr Surg; 2015; 31(2):83-8. PubMed ID: 25564257
[TBL] [Abstract][Full Text] [Related]
19. Relative Rise of Serum IgG4 Levels After Steroid Therapy for Autoimmune Pancreatitis Predicts the Likelihood of Relapse.
Suzuki D; Shimizu K; Tokushige K
Pancreas; 2018 Apr; 47(4):412-417. PubMed ID: 29517627
[TBL] [Abstract][Full Text] [Related]
20. IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients.
Wallace ZS; Deshpande V; Mattoo H; Mahajan VS; Kulikova M; Pillai S; Stone JH
Arthritis Rheumatol; 2015 Sep; 67(9):2466-75. PubMed ID: 25988916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
